Literature DB >> 8478873

Minimum important difference between patients with rheumatoid arthritis: the patient's perspective.

G A Wells1, P Tugwell, G R Kraag, P R Baker, J Groh, D A Redelmeier.   

Abstract

OBJECTIVE: To determine the point at which differences in clinical assessment scores on physical ability, pain and overall condition are sufficiently large to correspond to a subjective perception of a meaningful difference from the perspective of the patient.
METHODS: Forty patients with a diagnosis of rheumatoid arthritis participated in an evening of clinical assessment and one-on-one conversations with each other regarding their arthritic condition. The assessments included tender and swollen joint counts, clinician and patient global assessments, participant assessment of pain and the Health Assessment Questionnaire (HAQ) on physical ability. After each conversation, participants rated themselves relative to their conversational partner on physical ability, pain and overall condition. These subjective comparative ratings were compared to the differences of the individual clinical assessments.
RESULTS: In total there were 120 conversations. Generally participants judged themselves as less disabled than others. They rated themselves as "somewhat better" than their conversation partner when they had a (mean) 7% better score on the HAQ, 6% less pain, and 9% better global assessment. In contrast, they rated themselves as "somewhat worse" when they had a (mean) 16% worse score on the HAQ, 16% more pain, and 29% worse global assessment.
CONCLUSIONS: Patients view clinically important differences in an asymmetric manner. These results can provide guidance in interpreting results and planning clinical trials.

Entities:  

Mesh:

Year:  1993        PMID: 8478873

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  147 in total

Review 1.  Determination of the clinical importance of study results.

Authors:  Malcolm Man-Son-Hing; Andreas Laupacis; Keith O'Rourke; Frank J Molnar; Jeffery Mahon; Karen B Y Chan; George Wells
Journal:  J Gen Intern Med       Date:  2002-06       Impact factor: 5.128

2.  The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

3.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

4.  Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Weng Kee Wong; Joel Tsevat; Philip J Clements; Grace S Park; Arnold E Postlethwaite; Mansoor Ahmed; Shaari Ginsburg; Ron D Hays
Journal:  Qual Life Res       Date:  2007-04-03       Impact factor: 4.147

Review 5.  Prolotherapy in primary care practice.

Authors:  David Rabago; Andrew Slattengren; Aleksandra Zgierska
Journal:  Prim Care       Date:  2010-03       Impact factor: 2.907

6.  A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.

Authors:  S B Cohen; L W Moreland; J J Cush; M W Greenwald; S Block; W J Shergy; P S Hanrahan; M M Kraishi; A Patel; G Sun; M B Bear
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

7.  Clinically important change in quality of life in epilepsy.

Authors:  S Wiebe; S Matijevic; M Eliasziw; P A Derry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

8.  Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

Authors:  D van der Heijde; L Klareskog; A Singh; J Tornero; J Melo-Gomes; C Codreanu; R Pedersen; B Freundlich; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

9.  The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.

Authors:  M J Harrison; L M Davies; N J Bansback; M J McCoy; S M M Verstappen; K Watson; D P M Symmons
Journal:  Qual Life Res       Date:  2009-09-24       Impact factor: 4.147

10.  Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.

Authors:  Michael H Schiff; Elaine B Yu; Michael E Weinblatt; Larry W Moreland; Mark C Genovese; Barbara White; Amitabh Singh; Yun Chon; J Michael Woolley
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.